Loading clinical trials...
Loading clinical trials...
6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Prof David S Celermajer
NCT07365332 · Pulmonary Arterial Hypertension
NCT07218029 · Pulmonary Arterial Hypertension
NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension
NCT07120789 · Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), and more
NCT07457762 · Pulmonary Arterial Hypertension (PAH)
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions